Skip to main content
Aprogen, Inc logo

Aprogen, Inc — Investor Relations & Filings

Ticker · 007460 ISIN · KR7007460009 KO Manufacturing
Open in API
Filings indexed 737 across all filing types
Latest filing 2021-12-21 Capital/Financing Update
Country KR South Korea
Listing KO 007460

About Aprogen, Inc

https://www.aprogen.com/en/v.do?a=Main

Aprogen, Inc. is a biopharmaceutical company focused on the research, development, and manufacturing of biologic medicines. The company's core activities are centered on developing both biosimilars and novel drugs, including new protein therapeutics and bispecific antibodies. Its product development is based on proprietary technologies in antibody engineering and recombinant protein engineering.

Recent filings

Filing Released Lang Actions
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (Aprogen MED) detailing the adjustment of the conversion price for convertible bonds due to a decline in the market price of the underlying stock. This type of filing, which concerns changes to the terms of existing financial instruments (capital structure), falls under the 'Capital/Financing Update' category.
2021-12-21 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (Aprogen MED) regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most accurate fit as it covers updates on financing activities and capital structure changes, including adjustments to conversion prices of debt instruments.
2021-12-13 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate merger (회사합병 결정) between Aprogen Medicines and Aprogen. It details the merger schedule, exchange ratios, valuation methods, and shareholder rights (such as appraisal rights). This type of regulatory filing in the Korean market, which details M&A terms and conditions, is classified as M&A Activity (TAR).
2021-12-09 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a regulatory filing from a Korean company (Aprogen MED) titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders). It is a '정정신고' (Correction Report) regarding the date of an extraordinary general meeting. This document serves as a formal notice to shareholders regarding the scheduling and agenda (including board appointments and business purpose changes) for an upcoming meeting. It does not fit the criteria for a full Annual Report, Proxy Solicitation (which is typically a more comprehensive information statement), or a simple announcement of a report. Given the specific nature of the filing as a formal regulatory notice of a meeting, it falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides the necessary details for shareholders to attend and vote.
2021-12-09 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is an official regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most appropriate classification as it covers updates on financing activities and capital structure changes, including adjustments to conversion prices of debt instruments.
2021-11-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document is used to notify the financial authorities and the public when a person or entity acquires a significant stake (typically 5% or more) in a listed company. This falls under the 'Major Shareholding Notification' category.
2021-11-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.